Epitalon
Anti-Aging, Sleep
In short
- A synthetic tetrapeptide (Ala-Glu-Asp-Gly) from the Russian peptide bioregulator programme.
- Claims centre on telomerase activation and lifespan extension; the supporting studies are almost entirely from one research group in St Petersburg.
- Independent Western replication is essentially absent, which is the central problem with its evidence base.
- No human pharmacokinetic data exists.
- Research compound only, not approved anywhere.
Structure
How it works
Epitalon is a synthetic analogue of epithalamin, a pineal gland extract. The proposed mechanism is induction of telomerase activity, which would slow the telomere shortening that accompanies cell division, plus effects on melatonin rhythm and pineal function.
Telomerase induction in somatic cells is mechanistically double-edged: telomerase reactivation is also a feature of most cancers, which is why the same mechanism that motivates the longevity claim is a reason for caution.
What the research shows
Cell culture work from the originating group reported telomere elongation in human fibroblasts.
Rodent studies from the same programme reported increased lifespan and reduced tumour incidence.
Human studies reported from Russia describe effects on melatonin rhythm and mortality in elderly cohorts over long follow-up. These have not been independently replicated, are largely unavailable in English, and were not conducted to contemporary regulatory standards.
There is no independent trial confirming any of it.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rodent — lifespan and tumour incidence studies | Microgram-range dosing in intermittent courses; see source | — | PubMed |
| Human — Russian elderly cohort studies | Courses of injections repeated over years; see source for schedule | — | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, in courses of 10–20 days | 5–10 mg daily | subcutaneous |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. Community doses are also orders of magnitude above the amounts described in the original Russian work, which used microgram-range courses. That discrepancy is rarely acknowledged in vendor material.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous injection in intermittent courses rather than continuously is the pattern described in both the original studies and community use.
Side effects
No systematic safety data exists in any language accessible for independent review. Reported issues are minimal and limited to injection-site effects.
The theoretical concern follows directly from the claimed mechanism: a compound proposed to activate telomerase is proposed to do the thing that allows cells to divide indefinitely. Whether epitalon meaningfully induces telomerase in humans is unestablished, so this is a concern about the marketing claim as much as about the compound.
Combinations
No interaction data. Commonly combined with other Russian bioregulator peptides in community protocols, which compounds the absence of evidence rather than addressing it.
Research status
Developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology, where nearly all the supporting research originates.
The concentration of an entire evidence base in a single group that also advocates for the compounds is the specific methodological problem here, independent of whether the findings are correct.
Legal status
Not approved in the US, EU, or UK. Some peptide bioregulators are registered in Russia as dietary supplements or medicines. Sold in Western markets for research use only.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
Epitalon has the most dramatic claims in this library — telomerase activation and lifespan extension — attached to one of its thinnest independently verifiable evidence bases.
The rodent and human data may well be accurate. The problem is that essentially all of it comes from the group that developed and promotes the compound, and no independent lab has confirmed it in the decades since.
Sources
Track your own Epitalon protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.